.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Advanced Ovarian Cancer: Optimizing Therapy Based on Current Data

EP. 1: Neoadjuvant Chemo VS Cytoreductive Surgery in OC

November 28th 2018

EP. 2: Recommendations for Molecular Testing in Advanced OC

November 28th 2018

EP. 3: Upfront Systemic Therapy in Addition to Chemo?

November 28th 2018

EP. 4: Highly Anticipated Data from the SOLO-1 Trial

November 28th 2018

EP. 5: The Evolution of Single-Agent PARP Inhibitors

November 28th 2018

EP. 6: PARP Combinations: The Future

November 28th 2018

EP. 7: Role of HIPEC in Newly Diagnosed Advanced Peritoneal Cancer

November 28th 2018

EP. 8: Factors in Choice of Treatment for Recurrent Ovarian Cancer

November 28th 2018

EP. 9: Maintenance Therapy for Recurrent Advanced Ovarian Cancer

November 28th 2018

EP. 10: PARP Inhibitors: Which One Should We Use?

November 28th 2018

EP. 11: ADC in Platinum-Resistant Ovarian Cancer

November 28th 2018

EP. 12: The Role of I-O in Platinum-Resistant Recurrent OC

November 28th 2018

EP. 13: Novel Agents and the Future Treatment of Ovarian Cancer

November 28th 2018